Short and sweet: The latest with biotech
GeneQuine Biotherapeutics receives 9 Mil. EUR for Genetherapie
The Biotech startup GeneQuine Biotherapeutics GmbH has closed its Series A-financing round with 5,4 Mil. EUR and additionally collected convertible loans and funding of approximately 3,65 Mil. EUR.
GeneQuine Biotherapeutics, which has developed a gene therapeutic drug for the treatment of musculoskeletal diseases with a seed investment from the Innovationsstarter Fonds Hamburg, will use the capital to further develop the lead candidate GQ-303 for the treatment of osteoarthritis up to the clinical phase 1 study. The special thing about GeneQuine is that a single, local injection of the gene therapeutic drug should stimulate local protein production for several years, so that a repetition of the application is no longer necessary as with most conventional drugs.
https://www.vc-magazin.de/blog/2021/01/27/genequine-biotherapeutics-erhaelt-9-mio-eur-fuer-gentherapie/Lyra Health Closes $187M Series E Financing
Lyra Health, a Burlingame, Calif.-based provider of comprehensive mental health care benefits for employers, raised $187m in Series E financing round.
The round was led by Addition with participation from Durable Capital Partners LP, Fidelity Management & Research Company, and Baillie Gifford, along with other existing investors.
The company intends to use the funds to further expand its investments in tech-enabled mental health care, the provider network, and new partnerships.
